Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]
It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]
- Market Cap ₹ 2,701 Cr.
- Current Price ₹ 599
- High / Low ₹ 886 / 441
- Stock P/E 110
- Book Value ₹ 304
- Dividend Yield 0.00 %
- ROCE 6.01 %
- ROE 0.05 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Promoter holding has increased by 4.08% over last quarter.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.58% over past five years.
- Company has a low return on equity of -11.5% over last 3 years.
- Promoters have pledged or encumbered 39.0% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|
521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,289 | 1,284 | 1,239 | |
464 | 1,174 | 1,062 | 1,231 | 1,188 | 1,309 | 1,384 | 1,077 | 1,018 | |
Operating Profit | 57 | 213 | 260 | 386 | 81 | 134 | -95 | 206 | 221 |
OPM % | 11% | 15% | 20% | 24% | 6% | 9% | -7% | 16% | 18% |
2 | 12 | 27 | 29 | 16 | 22 | -185 | 8 | 9 | |
Interest | 25 | 82 | 78 | 84 | 75 | 90 | 105 | 115 | 108 |
Depreciation | 34 | 83 | 94 | 109 | 112 | 111 | 103 | 99 | 98 |
Profit before tax | 0 | 60 | 115 | 222 | -91 | -45 | -488 | 1 | 25 |
Tax % | -70% | 1% | 0% | 0% | -36% | -50% | 16% | 0% | |
0 | 59 | 115 | 221 | -58 | -22 | -567 | 1 | 25 | |
EPS in Rs | 17.30 | 32.01 | 46.22 | -12.11 | -4.62 | -118.21 | 0.15 | 6.79 | |
Dividend Payout % | 0% | 22% | 5% | 11% | 0% | -49% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -1% |
3 Years: | 0% |
TTM: | -5% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -66% |
3 Years: | 26% |
TTM: | 106% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -12% |
3 Years: | 14% |
1 Year: | -17% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -4% |
3 Years: | -11% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 25 | 26 | 27 | 36 | 36 | 36 | 36 | 40 |
Reserves | 739 | 930 | 1,059 | 1,553 | 1,489 | 1,464 | 898 | 1,054 |
633 | 538 | 722 | 621 | 1,037 | 1,013 | 1,012 | 796 | |
425 | 466 | 346 | 404 | 383 | 386 | 406 | 342 | |
Total Liabilities | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
1,086 | 1,218 | 1,397 | 1,382 | 1,356 | 1,364 | 1,268 | 1,193 | |
CWIP | 71 | 40 | 40 | 88 | 239 | 238 | 256 | 280 |
Investments | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
663 | 701 | 716 | 1,144 | 1,350 | 1,295 | 825 | 757 | |
Total Assets | 1,821 | 1,960 | 2,153 | 2,614 | 2,945 | 2,899 | 2,351 | 2,232 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
49 | 166 | 242 | 155 | -242 | 156 | 109 | 213 | |
-85 | -113 | -359 | -106 | -243 | -81 | -4 | -37 | |
68 | -23 | 97 | 92 | 334 | -113 | -106 | -180 | |
Net Cash Flow | 31 | 30 | -20 | 142 | -151 | -38 | -0 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 184 | 76 | 63 | 109 | 141 | 136 | 99 | 93 |
Inventory Days | 252 | 111 | 170 | 149 | 321 | 258 | 163 | 185 |
Days Payable | 420 | 127 | 132 | 156 | 154 | 142 | 142 | 145 |
Cash Conversion Cycle | 16 | 60 | 101 | 102 | 308 | 252 | 120 | 133 |
Working Capital Days | -124 | -22 | -32 | 16 | 37 | 20 | -128 | -62 |
ROCE % | 10% | 12% | 15% | -0% | 2% | -9% | 6% |
Documents
Announcements
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep - AGM Sep 25, 2025: approved audited financials; RPT with Strides up to ₹400 crore; two director appointments.
-
Closure of Trading Window
26 Sep - Trading window closed from October 1, 2025 until 48 hours after Sept 30, 2025 results declaration.
-
Announcement Under Regulation 30 SEBI (LODR) - Clarification
26 Sep - September 26, 2025 BSE volume movement response: company confirms all disclosures made, no withheld material information.
-
Clarification sought from Solara Active Pharma Sciences Ltd
26 Sep - Exchange has sought clarification from Solara Active Pharma Sciences Ltd on September 26, 2025, with reference to Movement in Volume.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 25 Sep
Annual reports
Concalls
-
Jul 2025TranscriptPPTREC
-
May 2025TranscriptPPTREC
-
Jan 2025Transcript PPT REC
-
Oct 2024Transcript PPT REC
-
Jul 2024TranscriptPPTREC
-
Jun 2024TranscriptPPTREC
-
Feb 2024TranscriptPPTREC
-
Nov 2023TranscriptPPTREC
-
Aug 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
May 2022Transcript PPT
-
Jul 2021TranscriptPPT
-
Apr 2021Transcript PPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
May 2020Transcript PPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Jul 2018TranscriptPPT
Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]